arrow_back Back to App

Affordable Drug Manufacturing Act: Lower Prices, Increased Access

This act aims to lower prescription drug prices and increase their availability for citizens. It establishes a new government office to manufacture essential drugs like insulin and asthma inhalers, ensuring affordability and supply, especially during shortages.
Key points
Creation of an Office of Drug Manufacturing within the Department of Health and Human Services to produce drugs, aiming to lower prices and increase competition.
The Office will prioritize manufacturing drugs with the greatest impact on reducing patient costs, including insulin, asthma inhalers, naloxone, and epinephrine.
Drug prices set by the Office will be fair, considering patient access and costs to health programs.
Prohibition of former drug industry lobbyists and senior executives from law-breaking companies from being employed by the new Office.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_6607
Sponsor: Rep. Schakowsky, Janice D. [D-IL-9]
Process start date: 2023-12-05
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Affordable Drug Manufacturing Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_6607.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-12-05.

What are the main provisions?

Key points include:

  • Creation of an Office of Drug Manufacturing within the Department of Health and Human Services to produce drugs, aiming to lower prices and increase competition.
  • The Office will prioritize manufacturing drugs with the greatest impact on reducing patient costs, including insulin, asthma inhalers, naloxone, and epinephrine.
  • Drug prices set by the Office will be fair, considering patient access and costs to health programs.
  • Prohibition of former drug industry lobbyists and senior executives from law-breaking companies from being employed by the new Office.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Schakowsky, Janice D. [D-IL-9].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health